Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk

Cancer Epidemiology

Volumn 34, Issue 3, 2010, Pages 328-337

  Ashton, Katie A ^a   Proietto, Anthony ^a,b   Otton, Geoffrey ^a,b   Symonds, Ian ^a   McEvoy, Mark ^a   Attia, John ^a   Gilbert, Michael ^c   Hamann, Ute ^c   Scott, Rodney J ^a,d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Endometrial cancer; Estrogen; Estrogen metabolism; Polymorphisms; Steroidogenesis

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ESTROGEN RECEPTOR ALPHA; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GUANINE; STEROID HORMONE; THYMINE;

ADULT; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CANCER; ESTROGEN METABOLISM; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LONG TERMINAL REPEAT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEROID METABOLISM; STEROIDOGENESIS;

ARYL HYDROCARBON HYDROXYLASES; BIOSYNTHETIC PATHWAYS; ENDOMETRIAL NEOPLASMS; ESTRADIOL DEHYDROGENASES; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE FREQUENCY; GONADAL STEROID HORMONES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ANDROGEN; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR MARKERS, BIOLOGICAL;

EID: 77952320363     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.03.005     Document Type: Article

References (46)

1. Akhmedkhanov A., Zeleniuch-Jacquotte A., and Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 943 (2001) 296-315
2. AIHW, Australian Institute of Health and Welfare (AIHW). Cancer in Australia: an overview, 2006. Cancer series no. 37. Available online at: www.aihw.gov.au/publications/index.cfm/title/10476. Published on June 28, 2007. ISBN: 13 978 1 74024 696 5.
3. Bakkum-Gamez J.N., Gonzalez-Bosquet J., Laack N.N., Mariani A., and Dowdy S.C. Current issues in the management of endometrial cancer. Mayo Clin Proc 83 1 (2008) 97-112
4. Zhu B.T., and Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19 1 (1998) 1-27
5. Lee A.J., Cai M.X., Thomas P.E., Conney A.H., and Zhu B.T. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144 8 (2003) 3382-3398
6. Weisz J., Bui Q.D., Roy D., and Liehr J.G. Elevated 4-hydroxylation of estradiol by hamster kidney microsomes: a potential pathway of metabolic activation of estrogens. Endocrinology 131 2 (1992) 655-661
7. Mooberry S.L. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Update 6 6 (2003) 355-361
8. Zhu B.T., and Conney A.H. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?. Cancer Res 58 11 (1998) 2269-2277
9. Liehr J.G. Is estradiol a genotoxic mutagenic carcinogen?. Endocr Rev 21 1 (2000) 40-54
10. Cavalieri E.L., Stack D.E., Devanesan P.D., Todorovic R., Dwivedy I., Higginbotham S., et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 94 20 (1997) 10937-10942
11. Yager J.D. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27 (2000) 67-73
12. Doherty J.A., Weiss N.S., Freeman R.J., Dightman D.A., Thornton P.J., Houck J.R., et al. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14 2 (2005) 357-366
13. Dawling S., Roodi N., Mernaugh R.L., Wang X., and Parl F.F. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 61 18 (2001) 6716-6722
14. Belanger A., Hum D.W., Beaulieu M., Levesque E., Guillemette C., Tchernof A., et al. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J Steroid Biochem Mol Biol 65 1-6 (1998) 301-310
15. Hayes J.D., Flanagan J.U., and Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 45 (2005) 51-88
16. Kala Z., Dolina J., Marek F., and Izakovicova Holla L. Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus. J Hum Genet 52 6 (2007) 527-534
17. Adjei A.A., Thomae B.A., Prondzinski J.L., Eckloff B.W., Wieben E.D., and Weinshilboum R.M. Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br J Pharmacol 139 8 (2003) 1373-1382
18. Nowell S., Ambrosone C.B., Ozawa S., MacLeod S.L., Mrackova G., Williams S., et al. Relationship of phenol sulfotransferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol. Pharmacogenetics 10 9 (2000) 789-797
19. Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., et al. The influence of the cyclin D1 870 G > A polymorphism as an endometrial cancer risk factor. BMC Cancer 8 (2008) 272
20. Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol (2009)
21. Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., et al. Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG 116 8 (2009) 1053-1061
22. Ashton K.A., Proietto A., Otton G., Symonds I., and Scott R.J. Genetic variants in MUTYH are not associated with endometrial cancer risk. Hered Cancer Clin Pract 7 1 (2009) p3
23. Miller S., Dykes D., and Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 3 (1988) 1215
24. Dupont W., and Plummer W. PS power and sample size program available for free on the internet. Controlled Clin Trials 18 274 (1997)
25. Schweizer P., Moisio A.L., Kuismanen S.A., Truninger K., Vierumaki R., Salovaara R., et al. Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer. Cancer Res 61 7 (2001) 2813-2815
26. McCaskie PA, Carter KW, Palmer LJ. A comprehensive modelling framework and a multiple-imputation approach to haplotypic analysis of population-based data. SimHap: [online] at: http://www.genepi.com.au/projects/simhap/; 2004.
27. Hirata H., Hinoda Y., Okayama N., Suehiro Y., Kawamoto K., Kikuno N., et al. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 112 9 (2008) 1964-1973
28. McGrath M., Hankinson S.E., Arbeitman L., Colditz G.A., Hunter D.J., and De Vivo I. Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 25 4 (2004) 559-565
29. Rebbeck T.R., Troxel A.B., Wang Y., Walker A.H., Panossian S., Gallagher S., et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst 98 18 (2006) 1311-1320
30. Rylander-Rudqvist T., Wedren S., Jonasdottir G., Ahlberg S., Weiderpass E., Persson I., et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 13 9 (2004) 1515-1520
31. Sasaki M., Tanaka Y., Kaneuchi M., Sakuragi N., and Dahiya R. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res 63 14 (2003) 3913-3918
32. Tao M.H., Cai Q., Zhang Z.F., Xu W.H., Kataoka N., Wen W., et al. Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 16 5 (2007) 943-949
33. Aklillu E., Oscarson M., Hidestrand M., Leidvik B., Otter C., and Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 61 3 (2002) 586-594
34. Hanna I.H., Dawling S., Roodi N., Guengerich F.P., and Parl F.F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60 13 (2000) 3440-3444
35. Esteller M., Garcia A., Martinez-Palones J.M., Xercavins J., and Reventos J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 75 9 (1997) 1385-1388
36. Cai Q., Gao Y.T., Wen W., Shu X.O., Jin F., Smith J.R., et al. Association of breast cancer risk with a GT dinucleotide repeat polymorphism upstream of the estrogen receptor-alpha gene. Cancer Res 63 18 (2003) 5727-5730
37. Boyapati S.M., Shu X.O., Ruan Z.X., Cai Q., Smith J.R., Wen W., et al. Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival. Clin Cancer Res 11 3 (2005) 1093-1098
38. Sand P., Luckhaus C., Schlurmann K., Gotz M., and Deckert J. Untangling the human estrogen receptor gene structure. J Neural Transm 109 5-6 (2002) 567-583
39. Weiderpass E., Persson I., Melhus H., Wedren S., Kindmark A., and Baron J.A. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis 21 4 (2000) 623-627
40. Buchanan G., Yang M., Cheong A., Harris J.M., Irvine R.A., Lambert P.F., et al. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13 16 (2004) 1677-1692
41. Chamberlain N.L., Driver E.D., and Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22 15 (1994) 3181-3186
42. Irvine R.A., Ma H., Yu M.C., Ross R.K., Stallcup M.R., and Coetzee G.A. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 9 2 (2000) 267-274
43. Sasaki M., Sakuragi N., and Dahiya R. The CAG repeats in exon 1 of the androgen receptor gene are significantly longer in endometrial cancer patients. Biochem Biophys Res Commun 305 4 (2003) 1105-1108
44. Yaron M., Levy T., Chetrit A., Levavi H., Sabah G., Schneider D., et al. The polymorphic CAG repeat in the androgen receptor gene in Jewish Israeli women with endometrial carcinoma. Cancer 92 5 (2001) 1190-1194
45. Ju W., and Kim S.C. Polymorphisms in CAG active allele length of the androgen receptor gene are not associated with increased risk of endometrial cancer. Cancer Genet Cytogenet 172 2 (2007) 178-179
46. McGrath M., Lee I.M., Hankinson S.E., Kraft P., Hunter D.J., Buring J., et al. Androgen receptor polymorphisms and endometrial cancer risk. Int J Cancer 118 5 (2006) 1261-1268